Structural Changes in Silicon Rubber Peritoneal Dialysis Catheters in Patients using Mupirocin at the Exit Site

Structural damage to polyurethane PD (peritoneal dialysis) catheters in patients using mupirocin ointment is widely appreciated, but damage to silicon rubber PD catheters is less well described. Ten catheters (6.6%) out of 152 were found to have structural alterations such as opacification, ballooning, thinning, and rupture. The duration of PD in these 10 patients ranged from 23 months to 80 months (mean duration 51.1 months). The frequency of mupirocin application varied from daily (2 cases) to 2-3 times per week (7 cases). In eight catheters opacification occurred at the exit site whereas one catheter showed opacification midway between the exit site and the titanium adaptor. One catheter showed opacification, ballooning, and thinning at the exit site ruptured in the form of two slit-like openings. In conclusion, various structural changes such as opacification, ballooning or thinning were seen in 6.6% of silicon rubber PD catheters in patients using mupirocin at the exit site. Although the mechanism remains elusive, mupirocin or the antiseptic solution alone or in combination may be contributory. We believe that this is an under-reported complication and encourage other health care givers to incorporate a search for such changes during clinic visits.

Reverse epidemiology in peritoneal dialysis patients: the Canadian experience and review of the literature

High Body Mass Index (BMI) has been associated with improved survival of End-Stage Renal Disease (ESRD) patients on chronic hemodialysis (HD); however, studies on the relationship of BMI with survival in Peritoneal Dialysis (PD) patients have yielded conflicting results. The purpose of this study was to evaluate the impact of BMI on survival of Canadian ESRD patients on PD, correcting for their age, sex, race, diabetes mellitus, and arterial hypertension. In an intent to treat study, we reviewed data of the Canadian Organ Replacement Register (CORR), of incident patients, starting PD between 1994 and 1998 and followed up from their initial PD treatment to the end of 2003. Patients were censored at loss to follow up, transplantation, and the end of the observation period. Cox regression (multivariate) analysis was performed and adjustments were made for age, gender, race, primary renal disease and BMI. During these years, 4054 patients commenced PD, 1742 (43%) of them were females and 1471 (36.3%) were diabetics. The majority were Caucasians (n=3058, 75.4%); 120 (3%) belonged to the First Nations, 137 (3.4%) were black, and the rest (739 pts-18.2%) belonged to various other ethnicities. Based on quartiles of the BMI distribution, 1130 patients (28%) had a BMI < 18.5 kg/m(2); 1163 (28.7%), 18.5-24.9 kg/m(2); 1214 (30%), 25-29.9 kg/m(2); 547 (13.5%) > 30 kg/m(2). Intent to treat Cox regression analysis showed that being underweight was a strong risk factor for death. Specifically, a BMI less than 18.5 was associated with a death hazard ratio (HR) 1.3, (CI: 1.1-1.6). On the contrary, BMI > 30 was not associated with worse survival than those with normal BMI (HR = 1.009, CI = 0.89-1.14). High-BMI patients should not be discouraged from PD just because of their size.

Anaphylaxis from topical bovine thrombin (Thrombostat) during haemodialysis and evaluation of sensitization among a dialysis population

BACKGROUND

Topical bovine thrombin (TBT) is used as a topical haemostatic agent in haemodialysis (HD) units and for surgical procedures. It has caused allergic reactions during surgical procedures, but no previous cases have been reported with dialysis usage.

OBJECTIVE

A case is reported of anaphylaxis due to TBT in an HD patient. This led to a determination of whether HD patients exposed to TBT develop specific IgE and IgG antibodies to TBT and an assessment of the frequency of allergic symptoms in HD patients as compared with peritoneal dialysis (PD) patients.

METHODS

A cross-sectional study of 100 HD and 52 PD patients was performed using a questionnaire to determine allergic symptoms. An ELISA assay was developed to determine TBT-specific IgE and IgG serum antibodies among HD patients. HD patients without TBT exposure and age- and gender-matched blood donors served as controls.

RESULTS

Allergic symptoms temporally related to dialysis reported by a questionnaire were significantly more frequent for HD patients than for PD patients: rhinoconjuctivitis 11% vs. 2%, asthma symptoms 20% vs. 6%, urticaria 23% vs. 8% (P values <0.05). Positive TBT-specific IgE and IgG antibodies were more frequent among 65 exposed HD patients (28% for IgE and 26% for IgG) than for controls (4% and 9%), P<0.05.

CONCLUSIONS

Results indicate the potential for sensitization and clinical allergic responses to beef thrombin when used for haemostasis in HD and suggest that other haemostatic methods should be considered.

Negative impact of Crohn's disease on bone mineral mass

Prolonged chronic inflammation and corticosteroid therapy increase the risk of osteoporosis in patients with Crohn's disease. It has been estimated that 30% of these patients, who take steroids for prolonged periods, will suffer a vertebral fracture. Patients with Crohn's disease are difficult to wean from corticosteroids and therefore are at risk of developing bone complications. The purpose of this cross-sectional study was to examine the relationship between cumulative steroid dose, duration of the disease and the development of osteopenia in patients with Crohn's disease. We studied 28 patients (17 men, 11 women) with Crohn's disease: eight had one or more bowel resections and all the women were premenopausal. Serum calcium, phosphate, total alkaline phosphatase, immunoreactive parathyroid hormone (iPTH), 25(OH)Vitamin D(3) and 1,25 (OH)(2) Vitamin D(3) were measured by autoanalyser methods or radioimmunoassay. Bone mineral density (BMD) was studied using dual energy X-ray bone absorptiometry of the lumbar spine (L2-L4) and the femoral neck. Of these 28 patients, 27 received an average of 17.3 +/- 21.7 g (range 1 to 80) g of prednisone over a period of 4 to 216 months. Fourteen out of the 28 patients had mildly diminished bone density (z-score >-2.5 SD and < -1 SD) of the spine and 15/28 of the hip. We found a greater decrease in bone density (z-score < -2.5 SD) in 2 out of 28 patients at the spine and in 5 out of 28 at the femoral neck. Those in whom the duration of the disease was less than two years (12 patients) had significantly higher vertebral z-scores (-0.096 +/-0.91) than those who had the disease for over two years (-1.31 +/- 2.37), (p<0.05). We found no significant correlation between lumbar spine and femoral neck z-scores and cumulative steroid therapy. Six out of 28 patients (four women and two men), of mean age 47.2+/-11.7, had one vertebral fracture. The mean cumulative dose of steroids (prednisone or budesonide) in patients with vertebral fractures was higher but not significantly different from that in patients without fractures -20.1+/-18.2 versus 14.1+/-11.2 g of prednisone, respectively (p>0.05). No correlation was found between various serum hormones and other biochemical parameters of bone turnover or bone density. We conclude that a large proportion of patients with Crohn's disease have reduced bone mineral density (58% at the spine and 75% at the femoral neck). The pathogenesis of bone loss is probably multifactorial. Although steroid therapy might be an important contributory factor, we were unable to find a significant correlation between it and bone loss. On the contrary, we observed that the duration of the disease makes a significant contribution to bone loss.

The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis

Among several regimes used in the oral treatment of continuous ambulatory peritoneal dialysis (CAPD)--related peritonitis, ciprofloxacin and ofloxacin showed the higher treatment efficacy, with an overall cure rate of 80% over a treatment duration of 10-16 days. The antimicrobial activity of these agents against gram-positive episodes was equal to or even higher than that against other peritonitis episodes, and the effectiveness of oral ciprofloxacin can be further increased either by an additional intraperitoneal dose for the first 1-5 days, or by a simultaneous intraperitoneal dose of vancomycin in the first 24 hours. Clinical resistance to the new quinolones has been uncommon. The possibly increasing resistance to ciprofloxacin is a consequence of suboptimal dosing, with the resulting low local concentrations of the antibiotic. Oral treatment with quinolones provides a good therapeutic alternative to more widely used antibiotics for initial treatment of peritonitis episodes. However, more extensive data from comparative randomized studies with agents administered orally and intraperitoneally would be able to clearly elucidate the overall safety and success of oral treatment of PD-related peritonitis with quinolones or any new agent.

Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection

OBJECTIVE

To determine the prevalence of the carriage of Staphylococcus aureus (SA), methicillin-resistant Staphylococcus aureus (MRSA), and mupirocin-resistant Staphylococcus aureus (MuRSA) in chronic peritoneal dialysis (CPD) patients after 4 years of prophylactic mupirocin application to the exit site, in a peritoneal dialysis unit.

METHODS

Three swabs were collected from the nares, axillae/groin, and exit site, respectively, from 149 patients on CPD between May and July 2001. All swabs were cultured on solid selective agar (mannitol salt agar) and in mannitol salt broth. Staphylococcus aureus isolates were tested for methicillin resistance using oxacillin screening plates, and mupirocin resistance using E-test strips. Low-level MuRSA was defined as minimum inhibitory concentration (MIC) of 4 mg/mL or more, and high-level MuRSA as MIC of 256 mg/mL or more.

RESULTS

Staphylococcus aureus was isolated from 26 (17%) patients (25 from nares/axilla/groin, and 1 from the exit site). High-level MuRSA was isolated from 4 patients (3% of the total study population; 15% of total SA isolates). No MRSA was detected. One patient with high-level MuRSA had peritonitis due to SA, resulting in treatment failure and catheter loss, soon after the swabs were collected for the study.

CONCLUSION

We report the emergence of high-level MuRSA in CPD patients after a 4-year practice of continuous use of mupirocin in a small number of patients in our unit. Our results may have significant implications for the future practice of prophylactic use of mupirocin by CPD patients to prevent exit-site infection.

Long-term survival with peritoneal dialysis in ESRD due to diabetes

Several clinical studies have evaluated the factors that affect survival rates and compared outcomes between CAPD and HD in diabetic patients. However, only a small number of diabetic PD patients have been followed for over 5 years, largely because of coexisting, far-advanced, target organ damage at the initiation of dialysis and its progression during the course of dialysis, the presence of various comorbid conditions at the start of dialysis and finally, the limitations of long-term PD. Among the various modes of renal replacement, many clinicians have favored continuous ambulatory peritoneal dialysis (CAPD) for the management of diabetic patients for several reasons. However, survival of diabetic patients undergoing peritoneal dialysis (PD) and hemodialysis (HD) is probably similar, while diabetics on CAPD have a lower actuarial survival and technique success rates than non-diabetic patients of comparable age. This paper reviews the literature and our experience concerning the long-term survival on peritoneal dialysis of diabetic patients with ESRD.

Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients

OBJECTIVE

To compare efficacy in anemia correction and side effects of large doses of intravenous (IV) iron dextran and iron saccharate preparations in peritoneal dialysis (PD) patients.

SETTING

Tertiary-care teaching hospital of University of Toronto.

DESIGN

Retrospective analysis of 379 PD patients who attended PD clinics in past 5 years. Of these 379 patients, 62 were selected to receive IV iron based on ferrokinetic markers of iron deficiency, noncompliance to or ineffectiveness of oral iron, or increased erythropoietin (EPO) requirement.

INTERVENTION

Sixty-one patients received two IV iron injections of 500 mg each, 1 week apart, 33 patients received iron dextran, 23 received iron saccharate, and 5 received both iron dextran and iron saccharate. One patient developed anaphylaxis to a test dose of iron dextran and was excluded from further therapy. Blood samples were collected before and 3 and 6 months after iron infusions.

RESULTS

At 3 months, the group's average hemoglobin rose from 98.3+/-18.3 g/L to 110.6+/-16.4 g/L (p < 0.0001). Ferritin rose from 104.9+/-115.4 microg/L to 391.5+/-294.1 microg/L (p < 0.0001), and transferrin saturation from 0.17+/-0.07 to 0.26+/-0.19 (p < 0.0001). Erythropoietin requirements fell from 7278.7 IU/week to 5900 IU/week (p < 0.01). Five of the 34 patients who received iron dextran developed minor side effects and 1 patient had anaphylaxis to the test dose. Of the 23 patients who received iron saccharate, 1 had an anaphylactic reaction and 2 had transient chest pain, which subsided without therapy. Overall, there were more side effects with iron dextran (7.4% of injections) compared to the iron saccharate group (4.3% of injections), but this difference was statistically insignificant. Although statistically insignificant, there was an increase in the number of peritonitis episodes during the 6 months after IV iron infusion, especially with iron dextran, compared to the peritonitis episodes during the 6 months before iron infusions.

CONCLUSION

Our study indicates that IV iron in PD patients is effective in restoring iron stores and in decreasing EPO requirements. One anaphylactic reaction occurred in each group. Our data suggest that as much caution be exercised with iron saccharate as with iron dextran. The slight trend toward increased peritonitis rates after iron infusions needs to be investigated in a larger group of patients.

Hyaluronan modifies inflammatory response and peritoneal permeability during peritonitis in rats

The effect of high-molecular-weight hyaluronan (HA) on peritoneal and systemic inflammation and peritoneal permeability to water and solutes was studied during endotoxin-induced peritonitis in rats. Acute peritonitis was induced by adding lipopolysaccharide (LPS) to the dialysis fluid (Dianeal 3.86; Baxter Healthcare, Ireland, Castlebar). HA was added to the dialysis solution in a concentration of 10 mg/dL. During 4- and 8-hour dwells of the dialysis fluid, we studied the intensity of peritoneal (dialysate) and systemic (blood) inflammation (dialysate cell count and differential, cytokine and HA levels), as well as the transperitoneal transport of solutes and water. In rats, the addition of LPS to the dialysis fluid induced changes in inflammatory reaction and transperitoneal transport similar to those seen in continuous ambulatory peritoneal dialysis patients with peritonitis. During peritonitis, the addition of HA to the dialysis fluid reduced the loss of ultrafiltration, which resulted in a greater peritoneal creatinine clearance during the 8 hours of dwell (29.9 +/- 6.7 mL/8 h in the HA-LPS group versus 19.7 +/- 7.8 mL/8 h in the LPS group; P < 0.05). Dialysate interferon-gamma (INF-gamma) levels during peritonitis were greater in HA-treated animals (536.8 +/- 296.6 pg/mL in the HA-LPS group versus 169.8 +/- 137.8 pg/mL in the LPS group; P < 0.05). Dialysate elastase activity increased during peritonitis (44.4 +/- 9.3 versus 14.2 +/- 4.1 U/mL in peritonitis-free rats); during peritonitis, the increase in dialysate elastase activity was less pronounced in the rats that had HA in the dialysate (27.3 +/- 4.1 U/mL versus the LPS group; P: < 0.01). We conclude that HA added to the dialysis fluid reduces loss of ultrafiltration during peritonitis in rats. In the presence of HA dialysate, INF-gamma levels during peritonitis increased, whereas elastase activity decreased; these changes might improve the peritoneal immune reaction during peritonitis and at the same time prevent peritoneal membrane injury.

Intraperitoneal hyaluronan administration in conscious rats: absorption, metabolism, and effects on peritoneal fluid dynamics

BACKGROUND

Hyaluronan (HA) is a major component of interstitial tissue that participates in fluid homeostasis, response to inflammation, and wound healing. Previous studies have shown that intraperitoneal administration of HA can affect peritoneal fluid transport during short peritoneal dialysis exchanges in anesthetized rats. We sought to investigate the effect of high molecular weight HA on peritoneal permeability in conscious rats during dialysis exchanges up to 8 hours in duration. In addition, we sought to investigate the absorption of HA from the peritoneal cavity, its accumulation in peritoneal tissues, and its metabolism in normal and uremic rats.

METHODS

Experiments were performed on male Wistar rats infused with 30 mL peritoneal dialysis solution (Dianeal, Baxter Healthcare; Castelbar, Ireland) containing 10 mg/dL HA or with Dianeal alone (control). Peritoneal fluid removal (net ultrafiltration), permeability to glucose, creatinine, and total proteins, and tissue and blood levels of HA were determined in separate groups of rats at 1,2, 4, 6, and 8 hours after intraperitoneal infusion. Hyaluronan appearance and disappearance from plasma were also studied for 24 hours in separate groups of normal and uremic rats.

RESULTS

Net ultrafiltration was significantly greater (27%) in rats infused with HA at 4, 6, and 8 hours (p < 0.01) compared to controls. Transperitoneal equilibration of protein was reduced by 27% (p < 0.001) at 4 hours and by 30% (p < 0.01) at 8 hours. During the 8-hour exchange, peritoneal clearance of creatinine increased by 27% (p < 0.01), whereas the clearance of total protein decreased by 27% (p < 0.005). After 8 hours, 25.7% +/- 3.1% of the administered HA was absorbed from the peritoneal cavity, peritoneal tissue HA concentration was increased by 117% (p < 0.001), and plasma HA levels increased by 435% (p < 0.001). Plasma HA levels returned to normal within 24 hours after intraperitoneal administration in both healthy and uremic rats.

CONCLUSIONS

Hyaluronan added to dialysis fluid is absorbed from the peritoneal cavity and accumulates in peritoneal tissues. Hyaluronan supplementation produces changes in peritoneal permeability, leading to higher net ultrafiltration and peritoneal creatinine clearance, whereas total protein clearance decreases. The HA that is absorbed from the peritoneal cavity appears to be rapidly metabolized in both healthy and uremic rats.

Long-term survival on peritoneal dialysis in end-stage renal disease owing to diabetes

Only a small number of peritoneal dialysis (PD) patients with diabetes have been followed for more than 5 years. Lack of extended follow-up for these patients is largely due to coexisting, far-advanced damage to target organs at initiation of dialysis, with progression of that damage during the course of dialysis; the presence of various comorbid conditions at the start of dialysis; and limits to long-term PD technique. Among renal replacement modalities, continuous ambulatory peritoneal dialysis (CAPD) has been favored by many clinicians for the treatment of diabetic patients owing to reasons inherent in the therapy. Reported survival rates of diabetic patients on CAPD vary from 17%-72% for the fourth year (mean value: 39%) and from 19%-63% for the fifth year (mean value: 35%). Diabetic patients have actuarial rates of patient survival and technique survival that are lower than those for non diabetic patients of comparable age on CAPD. Patient survival for diabetic patients undergoing PD is similar to that for diabetic patients on hemodialysis. Because the peritoneal membrane maintains its ability to adequately purify blood for a long time, CAPD remains a viable form of long-term renal replacement therapy for diabetic patients with end-stage renal disease.

Prevalence and causes of cough in chronic dialysis patients: a comparison between hemodialysis and peritoneal dialysis patients

Peritoneal dialysis (PD) and hemodialysis (HD) are both common forms of dialysis for patients with end-stage renal disease. A few case reports have suggested that cough is associated with PD. From 1991 to 1998, 17 patients being treated with PD at the Toronto Western Hospital demonstrated persistent cough severe enough for referral to a respirologist. Causes of cough, often more than one cause per patient, included asthma, post-nasal drip, gastroesophageal reflux disease (GERD), chronic obstructive pulmonary disease, congestive heart failure, allergic rhinitis, pleural effusion, and respiratory infection. The aim of this cross-sectional study was to establish the prevalence of cough among PD patients, to determine if PD patients more commonly have a dry persistent cough than do HD patients, and, if the latter case is true, the possible reasons for it. A detailed survey of 92 PD patients and 91 HD patients was conducted in 1998 and 1999 at the University Health Network. Survey questions inquired about patient respiratory symptoms since onset of dialysis. Charts were reviewed to obtain information on use of medications possibly relevant to cough. In the PD and HD groups, 52% and 23% were females (p = 0.001), and the mean ages were 59.1 and 60.1 years, respectively. Angiotensin converting enzyme (ACE) inhibitors had been taken by 65% (PD) and 55% (HD) of patients, and beta-blocking medications by 43% (PD) and 51% (HD). Since initiation of dialysis--mean 2.7 years (PD) and 3.7 years (HD)--22% of PD patients reported persistent cough versus 7% of HD patients (p = 0.003). Although no significant association was seen between cough and self-reported heartburn in HD patients (p = 0.439), a significant association between cough and self-reported heartburn was seen in PD patients: 67% of PD patients with persistent cough reported heartburn versus 29% of those without cough (p = 0.008). The findings suggest that GERD and associated cough are more common in PD patients than in HD patients, perhaps owing to increases in intra-abdominal pressure from the peritoneal dialysate.

A physiological analysis of hyponatremia: implications for patients on peritoneal dialysis

The basis for hyponatremia is a negative balance for sodium (Na+) plus potassium (K+) and/or a positive balance for water. In patients with normal renal function, vasopressin is needed to prevent the excretion of electrolyte-free water. Vasopressin is not important when there is little residual renal function. If hyponatremia is accompanied by a quantitatively appropriate gain in weight, this implies that a gain of electrolyte-free water was the basis for hyponatremia. In the absence of this weight gain, a loss of salts is to be suspected. If the extracellular fluid (ECF) volume is obviously low, hyponatremia is due to a deficit of NaCl, unless there is a deficit of K+. With a KCl deficit and a contracted ECF volume, there should also be a large shift of Na+ into cells, so metabolic alkalosis would not be an expected finding. In contrast, those patients with no change in weight who have a normal or expanded ECF volume are subdivided into those with a gain of solutes restricted to the ECF compartment (glucose, mannitol), or those with a deficit of solutes of intracellular fluid origin, which implies that a catabolic state (malnutrition) may be present.

Peritoneal dialysis in diabetic patients

Diabetes mellitus is the fastest growing cause of end-stage renal disease (ESRD) and has become the leading cause of such ESRD worldwide. In the United States, between 1984 and 1997, the proportion of new patients starting renal replacement therapies whose ESRD was caused by diabetes increased from 27% to 44.4%. Canada saw an increase from 16.5% in 1984 to 28.9% in 1997, and many European countries had similar increases. Among the modes of renal replacement, many clinicians have favored continuous ambulatory peritoneal dialysis (CAPD) for the treatment of diabetic ESRD for several reasons. Many studies have compared clinical outcomes in diabetic patients undergoing CAPD, and nondiabetic patients undergoing CAPD, or diabetic patients undergoing peritoneal dialysis (PD) and those undergoing hemodialysis (HD). However, only a small number of diabetic dialysis patients have been followed up for more than 5 years, largely because of the presence of several comorbid conditions at the start of dialysis and the coexistence of far-advanced target-organ damage at dialysis initiation and its progression during the course of dialysis. Diabetic patients undergoing PD and HD probably have similar survival, and those undergoing CAPD have lower survival and technique success rates than nondiabetic patients of comparable age. This article reviews the literature and our experience with diabetic patients undergoing PD and compares clinical outcomes in diabetic patients undergoing PD and HD.

Evaluation of the effect of uremia on peritoneal permeability in an experimental model of continuous ambulatory peritoneal dialysis in anephric rats

Anephric rats were maintained on continuous ambulatory peritoneal dialysis (CAPD). Peritoneal permeability was assessed during a standard 4-hour peritoneal equilibration test (PET) performed with Dianeal 3.86% (Baxter Healthcare, Deerfield, Illinois, U.S.A.). The effect of uremia on peritoneal permeability was evaluated in an experimental protocol in which each animal served as its own control. In each rat, PET1 (control) was performed before removal of kidneys and PET2 (uremia) was performed four days after removal of kidneys. Net ultrafiltration during a 4-hour exchange with Dianeal 3.86% was higher during PET1 (3.8 +/- 2.3 mL) than during PET2 (-1.3 +/- 3.3 mL), p < 0.05. Peritoneal permeability to urea and glucose was similar in both series. Transperitoneal equilibration of creatinine concentration was faster in uremic animals: D/P at 4 hours was 0.94 +/- 0.06 during PET2 versus 0.77 +/- 0.08 during PET1, p < 0.001. The opposite difference was seen for total protein: D/Px 1000 after a 4-hour dwell was 51.4 +/- 19.8 during PET2 versus 70.3 +/- 12.9 during PET1, p < 0.05. Our results show that uremia modifies the permeability of the peritoneum to both water and solutes.

Bioelectrical impedance analysis in the evaluation of the nutritional status of continuous ambulatory peritoneal dialysis patients

The authors evaluated the nutritional status of 47 continuous ambulatory peritoneal dialysis (CAPD) patients, 26 men (age 58.9 +/- 14.6 years, duration on CAPD 27.3 +/- 18.3 months) and 21 women (age 56.2 +/- 14.9 years, duration on CAPD 34.5 +/- 23.4 months), using subjective global assessment (SGA), an established method for the nutritional assessment of dialysis patients, and bioelectrical impedance analysis (BIA: body cell mass, fat mass, and phase angle). Of the studied patients, 19 were diabetic (age 59.7 +/- 13.8 years, duration on CAPD 29.2 +/- 19.7 months) and 28 were non diabetic (age 53.9 +/- 14.3 years, duration on CAPD 31.5 +/- 21.8 months. According to SGA, 24 patients were scored as well nourished (Group I), 18 as mildly malnourished (Group II), and 5 as moderately malnourished (Group III). No patient scored as severely malnourished (Group IV). Analysis of the main nutritional parameters for the subgroups revealed a proportional decrease in phase angle, with a statistically significant correlation (p < 0.009) between phase angle and SGA. No significant difference was seen in serum albumin levels between patients in Group I and Group II, but the mean level was significantly lower in patients in Group III compared to Group I. The nutritional and biochemical data in diabetic patients and non diabetic patients were not significantly different. BIA phase angle seems to be a simple and reliable method for the routine assessment of nutritional status in CAPD patients.

Lymph flow and lymphatic drainage of inflammatory cells from the peritoneal cavity in a casein-peritonitis model in sheep

The purpose of this study was to characterize the cellular responses in the peritoneal cavity and draining lymph in a sterile peritonitis model in conscious sheep. Lymph was collected from lymphatics that drained the peritoneal space (caudal mediastinal and thoracic ducts) as well as from lymph vessels that drained peripheral tissues (prescapular). Casein was used as the inflammatory agent. Dialysis solution (Dianeal 4.25%) containing 1g% casein and 25 microCi 125I-human serum albumin was infused into the peritoneal cavity in 50 ml/kg volumes. Peritoneal volumes increased from a mean infused volume of 1572 +/- 51 ml to a maximum of 2119 +/- 77 ml at 3 hours. Over 6 hours, the number of macrophages and lymphocytes in the peritoneal cavity remained relatively constant but the number of neutrophils increased from 9.9 +/- 4.2 x 10(7) to 9.2 +/- 1.9 x 10(9) total cells. Caudal lymph which drains directly from the peritoneal cavity through diaphragmatic stomata, demonstrated a 5 fold increase in flow rate over 6 hours following the Dianeal-casein infusion. Thoracic duct and prescapular flows declined approximately 70% and 50% respectively in the same time period. the concentration of lymphocytes and the lymphocyte outputs (product of volume and concentration) declined in all lymph compartments. No elevations in neutrophil numbers in the thoracic and prescapular lymph compartments were observed but neutrophil output in the caudal lymph increased steadily from 3.1 +/- 1.5 x 10(6) to 4.6 +/- 1.3 x 10(7)/hr at the 6 hour mark. We conclude that the major route of removal of inflammatory cells and fluid from the peritoneal cavity is through diaphragmatic lymphatics.

Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD

We have developed an immunological procedure for measuring advanced glycosylation end-products (AGEs) in serum. Using this method, we measured AGEs in healthy volunteers, patients with diabetes, renal failure without treatment and in patients with renal failure, treated with hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). We found that AGEs were moderately elevated in diabetics without renal failure and highly elevated in CAPD and HD patients irrespective of their glycemic status. AGE levels correlated significantly with creatinine levels but not with levels of glucose or patient age or sex. AGE levels were reduced significantly post-hemodialysis. Preliminary experiments have shown that circulating AGEs have a molecular weight of approximately 1.5 to 2.0 kDa. More studies are needed to establish if AGE measurements in serum are prognostic indicators of the complications of either diabetes or renal failure.

In vitro culture of human peritoneal mesothelium for investigation of mesothelial dysfunction during peritoneal dialysis

There is a growing need for more biocompatible peritoneal dialysis fluid formulations. Using a method of in vitro cell culture we have examined the effect of osmotic agents, antiseptics and drug additives on various functions of human peritoneal mesothelial cells (HPMC). We have demonstrated that glucose and amino acids reduce the HPMC proliferation rate in a dose-dependent manner. 3H-methyl-thymidine incorporation into HPMC exposed to either 1.1% amino acid mixture or 2.0% glucose was decreased to (mean +/- SD) 32.5 +/- 6.1% and 16.8 +/- 1.2% of the control level respectively. Cultured HPMC have been shown to produce a fibrinolytic activity which may be estimated by the rate of plasma clot lysis. This activity may be diminished following the pre-incubation with 2.0% glucose and 1.1% amino acid mixture. We have found that povidone-iodine exerts a dose-dependent cytotoxic effect towards HPMC as measured by the increased 86Rb or 3H-inulin release from radiolabelled cells. We have also demonstrated that insulin enhances the 86Rb uptake and stimulates the Na, K-ATPase activity in HPMC but on the other hand is capable of reducing the phospholipids secretion from HPMC. Glucose, hydrocortisone or verapamil have also been shown to inhibit the release of mesothelial phospholipids. These data indicate that the mesothelial cell culture provides a convenient model for testing the biocompatibility of peritoneal dialysis solutions and assessing the dysfunction of mesothelial cells during peritoneal dialysis.

51Cr-RBCs and 125I-albumin as markers to estimate lymph drainage of the peritoneal cavity in sheep

The purpose of this study was to compare the use of 125I-labeled human serum albumin (125I-HSA) and autologous 51Cr-labeled red blood cells (51Cr-RBCs) as lymph flow markers to estimate lymph drainage of the peritoneal cavity in conscious sheep. In one group, we assessed lymph drainage from the appearance of intraperitoneally administered tracer in the bloodstream. To determine distribution of drainage into discrete lymph compartments, in a second group of studies, lymph was collected from the caudal mediastinal lymph node and the thoracic duct, both of which are involved in lymphatic drainage of the ovine peritoneal cavity. Ringer lactate solution (50 ml/kg) containing 8-10 microCi each of 125I-HSA and 51Cr-RBCs was infused into the peritoneal cavity. Lymph drainage was calculated by dividing the change in mass of tracer in the blood or lymph compartments by the average intraperitoneal tracer concentration. In noncannulated animals, lymph drainage averaged over 6 h was higher with 125I-HSA as tracer (1.35 +/- 0.12 vs. 0.62 +/- 0.19 ml.h-1.kg-1 with 51Cr-RBCs). A similar pattern was noted in terms of drainage into the caudal lymphatic (0.89 +/- 0.23 and 0.52 +/- 0.19 ml.h-1.kg-1 with 125I-HSA and 51Cr-RBCs, respectively) and thoracic duct (0.16 +/- 0.06 and 0.05 +/- 0.02 ml.h-1.kg-1 with 125I-HSA and 51Cr-RBCs, respectively). Analysis of 125I-HSA and 51Cr-RBC concentrations in lymph and intraperitoneal fluid suggested sieving of RBCs at the diaphragmatic stomata or lymph nodes. Using 125I-HSA as tracer and combining data from noncannulated and cannulated sheep, we estimated peritoneal lymph drainage to be 1.35 ml.h-1.kg-1, with 66% of this flow drained by the caudal vessel, 22% by the parasternal pathway (right lymph duct), and 12% by the thoracic duct.

Lymphatic drainage of hypertonic solution from peritoneal cavity of anesthetized and conscious sheep

Lymphatic drainage of the peritoneal cavity may reduce ultrafiltration in continuous ambulatory peritoneal dialysis. We assessed lymphatic drainage of the peritoneal cavity in sheep under dialysis conditions by cannulation of the relevant lymphatic vessels and compared lymphatic drainage in anesthetized and conscious animals. Lymph was collected from the caudal mediastinal lymph node and the thoracic duct, both of which are involved in the lymphatic drainage of the ovine peritoneal cavity. Volumes of a hypertonic dialysis solution (50 ml/kg 4.25% Dianeal) containing 25 microCi 125I-human serum albumin were instilled into the peritoneal cavity, and lymph flows and the appearance of labeled protein in the lymphatic and vascular compartments were monitored for 6 h. Intraperitoneal pressures increased 4-5 cmH2O above resting levels after infusion of dialysate. On the basis of the appearance of tracer in the lymph, drainage of peritoneal fluid into the caudal lymphatic was calculated to be 3.09 +/- 0.69 and 14.14 +/- 2.86 ml/h in anesthetized and conscious sheep, respectively. Drainage of peritoneal fluid into the thoracic duct preparations was calculated to be 1.32 +/- 0.33 and 14.69 +/- 5.73 ml/h in anesthetized and conscious sheep, respectively. Significant radioactivity was found in the bloodstream, and at least a portion of this was likely contributed by the right lymph duct, which was not cannulated in our experiments.(ABSTRACT TRUNCATED AT 250 WORDS)

Effects of amino acid dialysate on appetite in CAPD patients

The use of amino acid (AA) dialysate in CAPD patients may have theoretical disadvantages, since protein ingestion is known to suppress food intake in humans disproportionately to its energy value. Therefore we measured subjective appetite and food intake of CAPD patients in a cross-over study of 16 subjects (age 22-75 years, BMI 19-31, > 3 months on CAPD, non-diabetic and not protein malnourished). They received, in random order, either 4 weeks of dextrose only (their usual treatment), or one AA (1%) exchange replacing the first dextrose exchange each day. Subjective measurements of food intake (3 day food record) and quantitative measurements of lunch time food intake were obtained during a morning dextrose exchange after 28 days of each regimen. Except for a reduction in feelings of fullness during the AA treatment, there were no effects on feelings of hunger/satiety, food appeal, lunch-time food intake, or on 3-day food intake. We conclude that the use of a daily AA (1%) dialysate for 4 weeks does not affect subjective appetite or food intake of CAPD patients. There may even be a beneficial effect as the feeling of fullness decreased with the AA treatment.

Lymphatic removal of dialysate from the peritoneal cavity of anesthetized sheep

Several investigators have suggested that the lymphatic circulation reduces ultrafiltration in continuous ambulatory peritoneal dialysis (CAPD). The purpose of this study was to assess lymphatic drainage of the peritoneal cavity directly in anesthetized sheep under dialysis conditions. Lymph was collected from the caudal mediastinal lymph node and the thoracic duct, both of which are involved in the lymphatic drainage of the ovine peritoneal cavity, and from the prescapular lymph node, which is not involved in peritoneal lymphatic drainage. Fifty ml/kg volumes of a mildly hypertonic dialysis solution (Dianeal 1.5%) containing 25 microCi 125I-human serum albumin were instilled into the peritoneal cavity, and lymph flows and the appearance of labeled protein in the lymphatic and vascular compartments were monitored for six hours. Following the instillation of dialysis fluid there was a tendency for lymph flow rates from the thoracic duct to increase but these changes were not significant. However, flow rates from the caudal lymphatic demonstrated significant increases, especially in the final three hours of the monitoring period. Only about 8% of the radiolabeled albumin was removed from the peritoneal cavity over six hours (that is, 92% was left in the peritoneal space). Of the albumin removed, approximately 17% of this was drained by abdominal visceral lymphatics into the thoracic duct. About 25% passed through the diaphragm into the caudal mediastinal lymph node and into efferent lymph. Since the efferent lymphatic duct of the caudal mediastinal node empties directly into the thoracic duct, about 42% of all protein removed from the peritoneal cavity of the sheep was ultimately transported to the thoracic duct.(ABSTRACT TRUNCATED AT 250 WORDS)

Lymphatic drainage of the peritoneal cavity in sheep

Lymphatic drainage of the peritoneal cavity has been investigated in anesthetized sheep. Studies involving intraperitoneal administration of a complex of Evans blue dye and bovine serum albumin demonstrated the existence of three anatomically distinct pathways. In the first pathway, dye is removed from the peritoneal cavity by diaphragmatic lymphatics that pass into caudal sternal lymph nodes. Efferent lymphatics from these nodes transport the material to cranial sternal lymph nodes. Efferent cranial sternal lymphatics then convey the material either directly or indirectly, via tracheal lymphatic trunks, to the right lymph duct. In the second pathway, the complex is transported from the peritoneal cavity by diaphragmatic lymphatics that pass into the caudal mediastinal lymph node. Efferent lymphatic ducts from this node transport the material to the thoracic duct. The third pathway appears to involve transport of the dye across the mesothelial lining of the abdominal viscera and removal from the interstitium by afferent visceral lymphatics. Material taken up in this manner is ultimately transported to the thoracic duct by efferent visceral lymphatics. Experiments involving measurements of lymphatic absorption of 125I-labeled human serum albumin from the peritoneal cavity indicated that, over the 6-h period studied, 4.55 +/- 1.20 and 1.43 +/- 0.56% of the injected tracer could be recovered in thoracic duct lymph and caudal mediastinal efferent lymph, respectively, and the sum of these values represented 26% of the recovered radioactivity. On the other hand, 16.95 +/- 6.93% of the injected radioactivity could be found in the blood over the same period.(ABSTRACT TRUNCATED AT 250 WORDS)

Immunoreactive parathyroid hormone and in vitro inhibition of erythropoiesis by uremic serum in patients on continuous ambulatory peritoneal dialysis

Inhibition of erythropoiesis in vitro by uremic serum is well established. The role of parathyroid hormone (PTH) as inhibitor of erythropoiesis is uncertain. To further elucidate this effect we correlated the in vitro growth of red cell progenitors (BFU-E) in the presence of uremic serum from 26 patients on continuous ambulatory peritoneal dialysis with levels of immunoreactive PTH in the serum. The patients had a mean hemoglobin level of 100 +/- 20.1 g/l. The BFU-E growth was 98.8 +/- 28.3% of control. No correlation between BFU-E growth and hemoglobin was found. A significant negative correlation between levels of immunoreactive PTH and BFU-E growth was found (p = 0.05). These results support the notion that PTH or PTH fragment(s) might be responsible for the in vitro inhibition of erythropoiesis by uremic serum in patients on continuous ambulatory peritoneal dialysis.

Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease

Twenty diabetics with end-stage renal disease who had never previously received dialysis treatment were treated with continuous ambulatory peritoneal dialysis for periods of two to 36 months (average, 14.5). Intraperitoneal administration of insulin achieved good control of blood sugar. Even though creatinine clearance decreased significantly (P = 0.001), control of blood urea nitrogen and serum creatinine was adequate. Hemoglobin and serum albumin levels increased significantly (P = 0.005 and 0.04, respectively). Similarly, there was a significant increase in serum triglycerides and alkaline phosphatase (P = 0.02 and 0.05). Blood pressure became normal without medications in all but one of the patients. Retinopathy, neuropathy, and osteodystrophy remained unchanged. Peritonitis developed once in every 20.6 patient-months--a rate similar to that observed in nondiabetics. The calculated survival rate was 93 per cent at one year; the calculated rate of continuation on ambulatory peritoneal dialysis was 87 per cent. We conclude that continuous ambulatory dialysis with intraperitoneal administration of insulin is a good alternative treatment for diabetics with end-stage renal disease.

Measurement of free and free-plus-peptide hydroxyproline fractions in plasma

Plasma hydroxyproline fractions--free-plus-peptide and free--were determined by a method involving centrifugal ultrafiltration and the procedure of Kivirikko et al. [Anal. Biochem. 19, 249 (1967)]. Within- and between-day precision (CV) for the combined fractions was 4--5% and 2.8--6%, respectively. Mean analytical recoveries of free hydroxyproline were 95.2% (87--109%) in the normal range, and 97% (91--108%) in the above-normal range. Normal ranges for plasma hydroxyproline fractions, based on data for 11 men and 19 women, were free-plus-peptide, 7.5--25.3; free, 4.9--22.7; and peptide (calculated), 0.1--5.1 mumol of hydroxyproline per litre, respectively. These ranges showed no sex-related differences and were gaussian in distribution. A factor was derived to transform data on concentrations in ultrafiltrate into plasma concentrations.

Measurement of free and free-plus-peptide hydroxyproline fractions in plasma

Plasma hydroxyproline fractions--free-plus-peptide and free--were determined by a method involving centrifugal ultrafiltration and the procedure of Kivirikko et al. [Anal. Biochem. 19, 249 (1967)]. Within- and between-day precision (CV) for the combined fractions was 4--5% and 2.8--6%, respectively. Mean analytical recoveries of free hydroxyproline were 95.2% (87--109%) in the normal range, and 97% (91--108%) in the above-normal range. Normal ranges for plasma hydroxyproline fractions, based on data for 11 men and 19 women, were free-plus-peptide, 7.5--25.3; free, 4.9--22.7; and peptide (calculated), 0.1--5.1 mumol of hydroxyproline per litre, respectively. These ranges showed no sex-related differences and were gaussian in distribution. A factor was derived to transform data on concentrations in ultrafiltrate into plasma concentrations.

A controlled trial of nondrolone decanoate in the treatment of uremic anemia

Thirty-seven male dialysis patients, from three university hospital centers known to have adequate iron B12, and folate stores, were entered into a controlled trial to study the effects of nandrolone decanoate (200 mg i.m. weekly) on their anemia. An initial six-month stabilization period was followed by a randomized 12-month study, with crossover between treatment and control groups occurring at six months. Patients received parenteral iron therapy plus oral folate throughout the trial. All serious illnesses or major blood losses excluded the patients from analysis. The 24 patients with remnant kidneys showed an increase in hemoglobin and hematocrit of 24% by the end of six months of treatment (P less than 0.005), with a corresponding decrement during the six months of control, but the five anephric patients showed no statistically significant change compared to those patients whose kidneys were in place during the study. Complications of treatment were minimal, with injection site hematoma the only significant local effect and a rise in triglyceride the only significant systemic disturbance. Despite the improvement in anemia, the disadvantages, including the high cost of treatment, the apparent plateauing of benefits by five months, the minimal subjective improvement in life style, the risk of i.m. injection, plus the long term effects of increased lipids, should limit this therapy to patients with remnant kidneys who have severe symptomatic anemia or frequent transfusion requirements.

Measurement of serum and plasma ionic calcium with the "Space-Stat 20 Ionized Calcium Analyzer"

Ca2+ was measured in sera and plasma from 36 normal subjects (18 men 23-57 years old, and 18 women 20-52 years old) with the Space-Stat 20 Ionized Calcium Analyzer. Within-day and between-day precision (CV) for commercial serum-based specimens varied from 0.64-0.96% and 1.1-3.8%, respectively, depending on their mean concentrations. Plasma and serum showed within-day CV's of 1.05 and 0.79%, respectively. The linear regression of serum Ca2+ (y) on plasma Ca2+ (x) was y = 0.63x + 0.45 mmol/litre with a highly significant (P less than 0.001) coefficient of correlation (r) of 0.69. An approximate 5% increase in the mean Ca2+ concentration in serum over that found in plasma is probably due to heparin complexing. No significant sex-related difference was observed for either serum or plasma. The mean Ca2+ concentration of 29 refrigerated specimens tended to decrease in seven days (by 2.3%, not statistically significant). The normal Ca2+ range in serum and plasma (n = 35) was 1.08-1.18 and 1.02-1.14 mmol/litre, respectively.

Measurement of serum and plasma ionic calcium with the "Space-Stat 20 Ionized Calcium Analyzer"

Ca2+ was measured in sera and plasma from 36 normal subjects (18 men 23-57 years old, and 18 women 20-52 years old) with the Space-Stat 20 Ionized Calcium Analyzer. Within-day and between-day precision (CV) for commercial serum-based specimens varied from 0.64-0.96% and 1.1-3.8%, respectively, depending on their mean concentrations. Plasma and serum showed within-day CV's of 1.05 and 0.79%, respectively. The linear regression of serum Ca2+ (y) on plasma Ca2+ (x) was y = 0.63x + 0.45 mmol/litre with a highly significant (P less than 0.001) coefficient of correlation (r) of 0.69. An approximate 5% increase in the mean Ca2+ concentration in serum over that found in plasma is probably due to heparin complexing. No significant sex-related difference was observed for either serum or plasma. The mean Ca2+ concentration of 29 refrigerated specimens tended to decrease in seven days (by 2.3%, not statistically significant). The normal Ca2+ range in serum and plasma (n = 35) was 1.08-1.18 and 1.02-1.14 mmol/litre, respectively.

Partial body calcium measurements on patients with renal failure

The bone calcium status of 39 patients with chronic renal failure on hemodialysis has been measured by in vivo neutron activation analysis (IVNAA) and reported in terms of a calcium bone index (CaBl) which relates the calcium in a patient to that in a normal person of the same height. In 20 of the 39 cases sequential measurements were made over periods of up to 40 mo. The results are compared with data obtained by radiology and by histological examination of bone biopsies. CaBl values varied from below normal to, in one case, above the range of normal. Many of the higher values were associated with demonstrable osteosclerosis. As found in previous work here with IVNAA, significantly low values of CaBl were associated with vertebral deformities; however, some patients with deformity had normal CaBl values, indicating that these had both local mineral loss (resulting in fracture) and osteosclerosis. Taken all together, the data suggest that more than half the patients have osteosclerosis. Sequential data showed no uniform response to treatment.